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Asthma Management
for Children and Adults

State of Maine
Asthma Prevention
and Control Program

Consider the diagnosis of “asthma” if:
1.
2.
3.

RECURRENT coughing, wheezing, or shortness of breath relieved by a bronchodilator
Objective response by spirometry (≥12% increase of FEV1 post bronchodilator)
Rule out conditions such as aspiration, GERD, airway anomaly, foreign body, cystic fibrosis, vocal cord dysfunction, or
COPD. GERD is a common co-morbidity. (If diagnosis in doubt, consult with an asthma specialist.)

Assess Asthma Severity:
Persistent vs. Intermittent
1.
2.
3.
4.
5.
6.

Persistent
Asthma

Symptoms >2 days per week OR
Awaken at night from asthma >2X per month OR
Limitation of activities, despite pretreatment for exercise induced asthma OR
More than 2 steroid bursts in 1 year OR
FEV1 <80% predicted OR low FEV1/FVC ratio (see below)
For children <4 years consider “persistent” if more than 4 episodes of wheezing in a year
AND parental history of asthma or eczema or wheezing between illnesses.

Treatment for Persistent Asthma:
Daily Inhaled Corticosteroids
(steps 2, 3 or higher)

Assess Response within 2-6 weeks
“Well Controlled” Asthma
1.
2.
3.
4.
5.
6.

Daytime symptoms <2 days per week AND
Awakening at night from asthma <2X per month AND
No limitation of activities AND
Less than 2 steroid bursts per year
FEV1 ≥ 80% predicted
FEV1/FVC:
FEV1/FVC
5-19 yrs ≥ 85%
20-39 yrs ≥ 80%
40-59 yrs ≥ 75%
60-80 yrs ≥ 70%

YES

NO

Follow the Stepwise
Approach Guideline
and consider step down
if well controlled for 3
consecutive months.
Then re-assess every 3 to
6 months.

Follow the Stepwise
Approach Guideline
and step up until well
controlled is achieved.
Re-assess in 2 to 6 weeks.

Quick Tips for
All Patients with Asthma
 Environmental Control: identify and avoid triggers
such as tobacco smoke, pollens, molds, animal dander,
cockroaches, and dust mites.
 Flu Vaccine: recommend annually.
 Spirometry: at diagnosis and at least annually.
 Asthma Score: use tools such as ACQ®, ACT™ or ATAQ© to
assess asthma control.
 Asthma Education: review correct inhaled medication
device technique every visit, if needed.
 Asthma Action Plan: at diagnosis; review and update at
each visit.
 Short-Acting Beta-Agonist (e.g., albuterol): 1) for quick
relief every 4-6 hours as needed (see step 1), 2) pretreat
with 2 puffs for exercise-induced bronchospasm 10-60
minutes before exercise.
 Oral Corticosteroids: consider for acute exacerbation.
 Spacer with Valve: if spacer selected, use spacer with
valve.
 Mask: use with spacer with valve and with nebulizer
for children <5 years and anyone unable to use correct
mouthpiece technique.
See www.coloradoguidelines.org for additional asthma management resources.

Consider referral to a specialist if not well controlled within
3-6 months using stepwise approach OR 2 or more ED visits
or hospitalizations for asthma in a year.

Adapted from the NAEPP 3: http://www.nhlbi.nih.gov/guidelines/asthma/. This guideline is designed to assist the clinician in the management of asthma. This guideline is not intended to replace the clinician’s judgment or establish a protocol for all patients with
a particular condition. For references, additional copies of the guideline, or patient documents go to www.coloradoguidelines.org or call (720) 297-1681 or 866-401-2092. This publication was supported by cooperative agreement #2U59EH824177-04 Revised,
from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. This Guideline was originally developed by Colorado Clinical Guidelines Collaborative.
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Asthma
Stepwise Approach
Intermittent
Asthma

State of Maine
Asthma Prevention
and Control Program

Persistent Asthma: Daily Medication
Step up as indicated although address possible poor
adherence to medication. Re-assess in 2 to 6 weeks.
Step down if well controlled and re-assess in 3 months.
If very stable then assess control every 3 to 6 months.
All LABAs and combination agents containing LABAs have a black box warning.

Step 6
Age 12+ yrs

Step 5
Age 12+ yrs

Step 4
Age 12+ yrs

Step 3
Age 12+ yrs

Step 2
All Ages

Step 1
(all ages)

Preferred:
Low-dose inhaled
steroid

Short-acting
beta-agonist (e.g.,
albuterol prn)

Alternative:
Leukotriene blocker
or cromolyn

If used more than 2
days per week (other
than for exercise)
consider
inadequate control
and the need to
step up treatment.

Preferred:
Low-dose inhaled
steroid + longacting
beta-agonist or
Medium-dose
inhaled steroid
Alternative:
Low-dose
inhaled steroid +
leukotriene blocker

Age 0-4 yrs

Age 5-11 yrs

Consider referral
(especially if
diagnosis is in
doubt)

Low-dose inhaled
steroid + longacting
beta-agonist
or leukotriene
blocker or
Medium-dose
inhaled steroid

Preferred:
Medium-dose
inhaled steroid +
long-acting beta
agonist
Alternative:
Medium-dose
inhaled steroid +
leukotriene blocker

Age 5-11 yrs
Same as 12+ yrs

Age 0-4 yrs
Medium-dose
inhaled steroid
+
either
long-acting
beta-agonist or
leukotriene
blocker

High-dose inhaled
steroid + longacting
beta-agonist
-andConsider
omaluzimab if
allergies

Age 5-11 yrs
Preferred:
High-dose inhaled
steroid + longacting
beta-agonist
Alternative:
High-dose
inhaled steroid +
leukotriene blocker

High-dose inhaled
steroid + longacting beta-agonist
+ oral steroid
-andConsider
omaluzimab if
allergies

Age 5-11 yrs
Preferred:
High-dose inhaled
steroid + longacting beta-agonist
Alternative:
High-dose
inhaled steroid +
leukotriene blocker
+
oral steroid

Age 0-4 yrs
Age 0-4 yrs
High-dose inhaled
steroid
+
either long-acting
beta-agonist or
leukotriene blocker

High-dose inhaled
steroid
+
either long-acting
beta-agonist or
leukotriene blocker
+
oral steroid

Age 0-4 yrs
Medium-dose
inhaled steroid +
referral

All ages Steps 4 through 6: Consult with asthma specialist

Consider immunotherapy if allergic asthma
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